Research shows CS18 restores drug sensitivity and reduces tumor growth in resistant cancer — Evidence Review

An experimental drug, CS18, was shown to weaken multiple cancer cell survival mechanisms and restore sensitivity to existing treatments in preclinical models. These findings from Baylor College of Medicine align with broader research, which underscores the complexity of cancer treatment resistance and the ongoing search for multi-targeted therapies.

• Cancer drug resistance remains a major obstacle, with numerous studies highlighting both genetic and non-genetic mechanisms that allow cancer cells to evade therapy and adapt to treatment pressures, supporting the rationale for agents like CS18 that disrupt multiple pathways at once 1 2 3 4 12 14 15.
• Previous research has identified the need for combination therapies and new targets to overcome resistance, especially in cancers that relapse after initial treatment efficacy, echoing the approach and potential impact of CS18 in restoring drug sensitivity and enhancing existing treatments 2 8 9 14 15.
• The specific challenge of resistance to drugs such as osimertinib in lung cancer has been widely documented, with studies emphasizing the heterogeneity of resistance mechanisms and the limited effectiveness of current options once resistance emerges, reinforcing the significance of CS18’s reported activity in resistant models 8 9 10.

Study Overview and Key Findings

Resistance to cancer therapy is a persistent challenge, often limiting the long-term effectiveness of treatments due to cancer cells' ability to activate alternative survival pathways. The present study addresses this by targeting TopBP1, a protein that coordinates several cellular processes involved in therapy resistance, with a novel compound, CS18. Unlike many prior approaches that focus on single resistance mechanisms, this study explores whether disrupting a central node can simultaneously impair multiple cancer survival strategies, offering a potentially broader solution to overcoming resistance.

Property	Value
Study Year	2026
Organization	Baylor College of Medicine
Journal Name	Science Advances
Authors	Fang-Tsyr Lin, Shwu-Jiuan Lin, Kang Liu, Yang Xiao, Lidija A. Wilhelms Garan, Helena Folly-Kossi, Weei-Chin Lin
Population	Cancer cell types including triple-negative breast cancer, ovarian cancer
Methods	Animal Study
Outcome	Cancer cell death, tumor growth reduction
Results	CS18 restored sensitivity to osimertinib in resistant lung cancer cells.

Literature Review: Related Studies

To place these findings in context, we searched the Consensus database of over 200 million research papers using the following queries:

1. cancer treatment resistance mechanisms
2. osimertinib sensitivity lung cancer
3. new drug candidates overcoming resistance

Summary Table

Topic	Key Findings
What mechanisms drive cancer drug resistance, and how can they be overcome?	- Resistance arises from genetic mutations, altered drug targets, enhanced DNA repair, apoptosis suppression, autophagy, and hypoxia 1 2 4 12 14 15. - Combination therapies, multi-targeted agents, and novel molecular targets are under investigation to circumvent resistance 14 15.
How does resistance to osimertinib develop in lung cancer, and what are current solutions?	- Osimertinib resistance is highly heterogeneous, involving both EGFR-dependent and independent mechanisms, including new mutations, gene amplifications, and exosomal protein transfer 8 9 10. - Combination strategies and agents targeting compensatory pathways are being explored to overcome resistance 8 9 10.
What are the prospects for new drug candidates in overcoming resistance?	- New agents that target multiple pathways or central molecular nodes may be more effective than single-targeted drugs 14 15. - Early-stage compounds and combination regimens have shown promise in restoring drug sensitivity in preclinical models 2 14 15.
Are combination therapies more effective at overcoming resistance than single agents?	- Combination approaches often yield better outcomes in resistant cancers but may increase side effects, necessitating careful evaluation 14 15. - Combining new agents (such as CS18) with existing drugs can restore or enhance treatment response in resistant models 14 15.

---

What mechanisms drive cancer drug resistance, and how can they be overcome?

Research consistently demonstrates that cancer drug resistance is a multifaceted problem, involving genetic mutations, epigenetic changes, altered protein expression, enhanced DNA repair, and adaptive cellular responses like autophagy and hypoxia. The new study’s approach—targeting a central protein that regulates several resistance pathways—aligns with current thinking that multi-pronged strategies are needed to effectively counteract resistance.

• Genetic and non-genetic mechanisms, including altered drug targets, gene amplifications, and microenvironmental factors, contribute to both intrinsic and acquired resistance 1 2 3 4 12 15.
• Enhanced DNA repair, apoptosis evasion, and changes in drug metabolism are frequently implicated in the failure of chemotherapy and targeted agents 1 2 4.
• Hypoxia and autophagy within the tumor microenvironment further promote resistance, making it difficult for single-target drugs to sustain efficacy 4 15.
• Novel therapeutic strategies focus on inhibiting or bypassing these resistance mechanisms, with multi-targeted agents and combination therapies showing particular promise 14 15.

How does resistance to osimertinib develop in lung cancer, and what are current solutions?

The challenge of resistance to osimertinib, a third-generation EGFR inhibitor used in non-small cell lung cancer, is well-documented. Resistance emerges through a variety of mechanisms, both involving the EGFR gene (such as secondary mutations) and independent pathways (such as gene amplifications and exosomal transfer of resistance factors). The CS18 study’s findings that sensitivity to osimertinib can be restored in resistant cells support ongoing efforts to find combination or adjunct therapies that address these diverse resistance routes.

• Resistance mechanisms include EGFR mutations (e.g., C797S), loss of T790M mutation, activation of bypass signaling pathways, and histological transformation 8 9.
• The tumor microenvironment and intercellular transfer of proteins via exosomes also play roles in mediating resistance 10.
• Patients with acquired resistance to osimertinib often have limited therapeutic options, highlighting the need for agents that can target multiple resistance mechanisms simultaneously 8 9.
• Combination therapies or new agents that disrupt compensatory pathways may re-sensitize resistant tumors to osimertinib 8 9 10.

What are the prospects for new drug candidates in overcoming resistance?

Emerging evidence favors drug candidates that can inhibit multiple survival pathways or central molecular nodes within cancer cells. The development of CS18 and similar agents reflects a growing focus on targets that act as “control centers,” potentially overcoming the redundancy and adaptability of cancer resistance mechanisms.

• Multi-targeted compounds and allosteric inhibitors are being designed to circumvent resistance arising from pathway redundancy or mutation 14 15.
• Preclinical studies show that combining new agents with existing drugs can restore efficacy in resistant cancer models 2 14 15.
• The design of structurally distinct inhibitors, such as CS18, aims to avoid cross-resistance with current therapies and address a broader range of resistance mechanisms 14.
• Continued evaluation in clinical settings will be critical to determine if these preclinical successes translate into improved patient outcomes 15.

Are combination therapies more effective at overcoming resistance than single agents?

Combination therapies have become a mainstay in efforts to combat cancer drug resistance, with evidence suggesting improved efficacy compared to monotherapies, particularly in resistant settings. However, these approaches must balance increased effectiveness with the potential for higher toxicity.

• Combining drugs with complementary mechanisms can prevent or delay the emergence of resistance, as seen in both preclinical and clinical studies 14 15.
• The use of agents like CS18 alongside established treatments (e.g., PARP inhibitors, osimertinib) has shown synergistic effects in preclinical models 14 15.
• Despite clear advantages, combination therapies may also increase the risk of adverse effects, necessitating careful optimization of dosing and scheduling 15.
• Future research will need to identify optimal combinations and patient populations most likely to benefit from these strategies 14 15.

Future Research Questions

While the preclinical results for CS18 are promising, further investigation is required to determine its safety, efficacy, and best use in clinical settings. Key questions pertain to the translation of these findings to humans, possible resistance to CS18 itself, and how such a strategy could integrate with the current standard of care. Understanding the broader applicability and long-term effects of disrupting central resistance nodes like TopBP1 will also be crucial.

Research Question	Relevance
How does CS18 perform in human clinical trials for cancer resistance?	Assessing CS18’s safety and efficacy in humans is critical before it can be considered for clinical use, as preclinical models do not always predict clinical outcomes 14 15.
Can cancer cells develop resistance to CS18 over time?	Understanding whether cancer cells can adapt to CS18 itself will inform the long-term viability and optimization of this therapeutic strategy 2 12 14.
What are the optimal combination partners for CS18 in different cancer types?	Identifying which existing drugs best synergize with CS18 could maximize therapeutic benefits and minimize toxicity, especially given heterogeneity among cancer types 14 15.
Does TopBP1 inhibition affect normal tissue function or cause toxicity?	Evaluating off-target effects and the role of TopBP1 in normal cells is essential to ensure the safety of this therapeutic approach 4 14.
How can multi-targeted agents be integrated into personalized cancer therapy?	Determining how agents like CS18 can be tailored to individual patients’ tumor biology may improve outcomes and reduce unnecessary side effects 15.